Stockreport

Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals [Yahoo! Finance]

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly. Acromegaly is a rare endocrine disease generally [Read more]